Literature DB >> 2158823

Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain.

J A Kramps1, C van Twisk, H Appelhans, B Meckelein, T Nikiforov, J H Dijkman.   

Abstract

Antileukoprotease or secretory leukocyte proteinase inhibitor is a potent serine proteinase inhibitor produced by exocrine glands of the human body. This monomeric protein (107 amino acids) comprises two homologous domains. It is generally thought that Leu19-Arg20-Tyr21 in the NH2-terminal domain represent the trypsin inhibitory activity, whereas Leu72-Met73-Leu74 in the COOH-domain represent the chymotrypsin and elastase inhibitory activity. Besides Met73, antileukoprotease contains three additional methionine residues all located in the COOH-terminal domain. Treatment of antileukoprotease with different amounts of methionine-selective reagents such as myeloperoxidase in the presence of H2O2 and Cl-, or cis-platinumdiammine dichloride resulted in a dose-dependent inactivation of all inhibitory activities, suggesting that methionine residues are involved in these activities. By using specific synthetic substrates, it was observed that elastase is able to displace trypsin from the inhibitor molecule, indicating that the trypsin and elastase inhibitory sites are located close to each other or at the same site. Incubation of antileukoprotease or its recombinant COOH-terminal domain with an antileukoprotease-specific monoclonal antibody (MoAb15) resulted in a strong selective increase of the trypsin inhibitory activity. The results presented reveal strong evidence that the inhibitory activities of antileukoprotease against trypsin, chymotrypsin and elastase are represented by its COOH-terminal domain, and that methionine residues are involved in interactions with these proteinases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158823     DOI: 10.1016/0167-4838(90)90202-q

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Secretory leukocyte protease inhibitor interferes with uptake of lipopolysaccharide by macrophages.

Authors:  A Ding; N Thieblemont; J Zhu; F Jin; J Zhang; S Wright
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Antibacterial activity of antileukoprotease.

Authors:  P S Hiemstra; R J Maassen; J Stolk; R Heinzel-Wieland; G J Steffens; J H Dijkman
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

3.  Basic trypsin-subtilisin inhibitor from marine turtle egg white: hydrodynamic and inhibitory properties.

Authors:  P C Sil; T K Chaudhuri; N K Sinha
Journal:  J Protein Chem       Date:  1993-02

4.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

5.  Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor.

Authors:  C Boudier; J G Bieth
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

6.  Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro.

Authors:  K Masuda; T Kamimura; K Watanabe; T Suga; M Kanesaki; A Takeuchi; A Imaizumi; Y Suzuki
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

7.  Expression and characterization of recombinant human secretory leukocyte protease inhibitor (SLPI) protein from Pichia pastoris.

Authors:  Zhiguo Li; Allison Moy; Kirti Sohal; Carolyn Dam; Peter Kuo; James Whittaker; Mei Whittaker; Nejat Düzgünes; Krystyna Konopka; Andreas H Franz; Joan Lin-Cereghino; Geoff P Lin-Cereghino
Journal:  Protein Expr Purif       Date:  2009-06-06       Impact factor: 1.650

8.  Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.

Authors:  Marie-Louise Zani; Kévin Baranger; Nicolas Guyot; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

9.  Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor.

Authors:  J Stolk; J Camps; H I Feitsma; J Hermans; J H Dijkman; E K Pauwels
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

10.  Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate.

Authors:  Kévin Baranger; Marie-Louise Zani; Valérie Labas; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.